Molecular structure of P32/98, CAS Number: 136259-20-6
P32/98 (CAS 136259-20-6)
See product citations (2)
Application:
P32/98 is a specific competitive transition-state substrate analog inhibitor of dipeptidyl peptidase IV
CAS Number:
136259-20-6
Purity:
≥98%
Molecular Weight:
260.4
Molecular Formula:
C9H18N2OS•1/2C4H4O4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
P32/98 is a specific, competitive transition-state substrate analog inhibitor of dipeptidyl peptidase IV (DPIV, DPPIV, and CD26). In obese Zucker and lean rats the inhibition of CD26's ability to hydrolyze Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP-1) lead to an increased secretion of insulin, especially in the obsese Rat, making P32/98 an important tool in diabetic research. P32/ 98 has also been shown to augment YY1-36's ability to enhance renovascular responses to angiotensin II in spontaneoulsy hypertensive rats. Due to CD26's effect on upregultating lymphocyte proliferation P32/98 has been demonstrated to decrease the lymphocyte proliferation.
P32/98 (CAS 136259-20-6) References
- Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. | Pospisilik, JA., et al. 2002. Diabetes. 51: 943-50. PMID: 11916911
- Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. | Pospisilik, JA., et al. 2002. Diabetes. 51: 2677-83. PMID: 12196458
- Quantitative analysis of dipeptidyl peptidase inhibitor P32/98 and its main metabolite in rat, dog, mouse, monkey, human plasma and human urine using liquid chromatography-tandem mass spectrometry: application to pharmacokinetic evaluation. | Meyer, A., et al. 2003. J Chromatogr B Analyt Technol Biomed Life Sci. 796: 401-11. PMID: 14581079
- Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. | Girardi, AC., et al. 2004. Am J Physiol Cell Physiol. 287: C1238-45. PMID: 15213057
- Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone. | Wargent, E., et al. 2005. Diabetes Obes Metab. 7: 170-81. PMID: 15715890
- Dipeptidyl peptidase IV: a molecular switch of vascular actions of neuropeptide Y. | Li, L., et al. 2006. Adv Exp Med Biol. 575: 135-40. PMID: 16700516
- Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. | Schön, E., et al. 1991. Biol Chem Hoppe Seyler. 372: 305-11. PMID: 1678607
- Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. | Schlatter, P., et al. 2007. Regul Pept. 141: 120-8. PMID: 17276524
- Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin II-mediated renal vasoconstriction in spontaneously hypertensive rats. | Jackson, EK., et al. 2007. J Pharmacol Exp Ther. 323: 431-7. PMID: 17726157
- Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance. | Augstein, P., et al. 2008. Diabetes Obes Metab. 10: 850-61. PMID: 17970756
- Effects of dipeptidyl peptidase iv inhibition on arterial blood pressure. | Jackson, EK., et al. 2008. Clin Exp Pharmacol Physiol. 35: 29-34. PMID: 18047624
- Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice. | Yazbeck, R., et al. 2008. Front Biosci. 13: 6850-8. PMID: 18508699
- Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. | Pederson, RA., et al. 1998. Diabetes. 47: 1253-8. PMID: 9703325
Inhibitor of:
CD26.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
P32/98, 10 mg | sc-201305 | 10 mg | $183.00 | |||
P32/98, 50 mg | sc-201305A | 50 mg | $774.00 |